Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is based on the Flutemetamol-PET senile plaque imaging to
investigate the peripheral blood biochemical and brain MRI imaging biomarkers and to research
completely independent intellectual property rights neuropsychological test tool for the MCI
due to AD. At the same time, the investigators will study the efficacy and safety of early
treatment of MCI due to AD by Huperzine A in 52 weeks.